Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia

NCT03528564 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT03528564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03528564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia
Lead sponsor
Unity Health Toronto
Phase
Phase 2
Overall status
Terminated
Start date
July 1, 2019
Completion date
May 31, 2021
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic disease, anemia, iron deficiency, hip arthropathy, knee arthropathy